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Abstract 
Two diseases of the modern world – Alzheimer’s and diabetes mellitus – are linked by 
epidemiology, genetics and molecular pathogenesis. They may also be linked by the 
remarkable observation that insulin signaling sets the limits on longevity. In worms, flies and 
mice, disrupting insulin signaling increases lifespan leading some to speculate that caloric 
restriction might extend lifespan in man. It is our contention that man is already a long lived 
organism, specifically with a remarkably high post-fertility life span, and that it is this that 
results in the high prevalence of Alzheimer’s and diabetes. We review evidence for this 
hypothesis that carries specific predictions including that other animals with exceptionally 
long post-reproductive lifespan will have increased risk of both diabetes and Alzheimer’s 
disease and present novel evidence that Dolphin, like man, an animal with exceptional 
longevity, might be one of the very few natural models of Alzheimer’s disease.  
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Main text 
Diabetes mellitus and Alzheimer’s disease 
As populations all over the world age, enormous challenges are posed by chronic disorders 
such as Alzheimer’s disease (AD) and type 2 diabetes mellitus (T2DM). Alzheimer’s disease 
in particular is a devastating condition. With a long prodromal period of perhaps ten to twenty 
years followed by another decade of clinical symptoms, AD and related dementia conditions 
are becoming a priority for many governments, not least as it is estimated that 1% of global 
GDP is spent on dementia care 
(http://www.alz.co.uk/research/files/WorldAlzheimerReport2010.pdf). As well as growing 
older, the populations of the developed economies are also growing obese and sedentary. 
Whilst this is most marked in the developed nations, it is truly an international trend and as 
children in particular show dramatic increases in body mass index, this is a deeply 
concerning indicator of health problems to come. These health problems are significant as 
obesity increases risk of cancers, cardiovascular disease and metabolic syndromes 
including T2DM.  
 
These two health challenges – an ageing population at risk of neurodegenerative disease 
such as AD, and an increasingly obese population at risk of metabolic conditions such as 
T2DM – may seem unconnected and unfortunate consequences of modern civilization. It 
could be suggested that improved health care and sanitation leading to older populations, 
combined with seemingly unlimited access to highly processed and calorific foods and an 
increasingly sedentary lifestyle suggests entirely independent and environmental, or more 
specifically social and historical, causes of the twin challenges of AD and T2DM. It is our 
contention however, that this construct is only partially explanatory and that there is a 
molecular link between longevity and both AD and T2DM that suggests a relationship 
 4 
whereby both arise not as an unfortunate consequence of growing older in the modern 
world, but are intrinsic to it. In other words that AD and T2DM are conditions not of ageing 
as they are usually considered, but of longevity. It is not so much how long an organism 
lives for that governs whether the organism is vulnerable in particular to AD, but the 
molecular mechanisms that underlie this period; a period that is highly characteristic for any 
given species. Moreover, that this longevity-associated disease risk explains why AD and 
T2DM are disorders principally of man. Here we propose a hypothesis that AD and T2DM 
are the price we pay for the molecular underpinning that allows us to be almost uniquely 
long-lived animals. 
 
Alzheimer’s disease is a form of dementia characterised by two main pathological lesions, 
the amyloid plaque and the neurofibrillary tangle. Whilst it remains contentious whether 
these lesions are themselves causative of the neuronal loss that results in functional deficits 
or whether they are simply indicative of an underlying process, the evidence from molecular 
genetics and experimental neuroscience is compelling that the amyloid cascade is at the 
heart of the pathology of AD [1]. This cascade involves first the generation of beta amyloid 
(A) from the Amyloid Precursor Protein (APP) and subsequently the aggregation of highly 
phosphorylated tau protein. Other processes including neuroinflammation clearly play a role, 
perhaps to exacerbate the amyloid cascade, perhaps triggered by the cascade or perhaps 
independently. In addition to genetic causes of familial early onset AD and genetic influences 
on late onset AD, a considerable effort has been expended on searching for environmental 
influences on AD. Despite this, relatively few have been identified and arguably, other than 
age itself only two – head injury and obesity/diabetes – have been unambiguously replicated 
[2, 3]. The evidence that diabetes and obesity increase the risk of dementia has been 
consistently reported from many epidemiological studies, themselves the subject of multiple 
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systematic reviews [4-9]. The mechanism underlying this risk might be at multiple levels, the 
most parsimonious of which might be that metabolic complications increases vascular 
damage to the brain and this either exacerbates AD pathology or is an additive or 
independent insult [3]. However, insulin resistance predicts the development of cerebral 
amyloid pathology as measured by PET imaging [10] and considerable evidence from cell 
and animal models suggests that a failure of insulin signaling directly contributes to AD 
pathological processes, including the formation of tau pathology as we discuss below.  
 
Insulin actions: role of Glycogen Synthase Kinase – 3 (GSK-3)  
For a failure of insulin signaling to effect the risk of AD directly rather than through a 
mediating factor such as vascular damage, then insulin resistance in the periphery should 
be reflected in insulin resistance in the brain. Considerable evidence suggests that this is in 
fact the case [11-13]. For example, in mid-life, peripheral insulin resistance is associated 
with central glucose metabolic abnormality as well as with poorer cognitive performance [14, 
15] and predicts amyloid deposition [10]. In turn, there is evidence that central insulin 
signaling failure or abnormality can induce peripheral insulin resistance. In mice, ablation of 
insulin receptors (IR) either from the whole brain (neuronal-specific IR knockout, NIRKO) or 
specifically from hypothalamus or midbrain dopamine neurons, induces hyperphagia, body 
weight gain, and peripheral insulin resistance [16],[17],[18]. Also, brain-specific genetic 
inactivation of the insulin receptor substrate 2 (IRS2) that is essential for insulin signaling, 
results in obesity and diabetic phenotypes [19].  
 
These data demonstrate a critical link between the CNS and the periphery and, importantly, 
both mice lacking the neuronal insulin receptor and those with IRS2 deleted are 
characterized by elevated tau phosphorylation and cognitive alterations, both characteristics 
 6 
of AD [20, 21]. Moreover, animal models of aspects of AD pathology show dysregulated 
metabolism [22] providing further experimental evidence for an intertwining of the molecular 
mechanisms of metabolic function and insulin signaling with AD. This link, and the increased 
risk of dementia in people with diabetes, suggests that there may be therapeutic 
opportunities for AD in enhancing insulin signaling, or tackling insulin resistance. Real-world 
data studies suggest that the commonly used therapy for T2DM, Pioglitazone a PPAR 
agonist that enhances insulin signalling, reduces the incidence of AD, [23] and intranasal 
insulin beneficially alters APP processing and reduces cognitive impairment in early AD [24-
26]. Large-scale trials of both intranasal insulin and pioglitazone are now underway. Whilst 
the outcomes of these trials are some years away it is clear that systemic insulin signaling 
disruption increases the risk of AD and might do so through shared molecular mechanisms 
and not simply through end-organ damage as a consequence of vascular or other T2DM-
induced pathology.  
 
One such molecular mechanism that might plausibly underlie this link between insulin 
signaling in the brain and AD processes is mediated by Glycogen Synthase Kinase-3 (GSK-
3) initially discovered through its ability to phosphorylate glycogen synthase [27]. Given its 
critical role in insulin signaling it is not surprising that GSK-3 has been implicated in the 
pathogenesis of obesity and insulin resistance [28, 29], but it has also been shown to have 
a fundamental role in the pathogenesis of AD [30, 31]. Tau is a physiological substrate of 
GSK-3 and transgenic mice with increased GSK-3 activity have neurodegeneration 
phenotypes including tau hyperphosphorylation and cognitive impairments [32]. Even before 
neurodegeneration sets in, GSK-3 over-activity suppresses long term potentiation (LTP) 
[33], whilst inhibition of GSK-3 is required following LTP to block long term depression (LTD) 
[34] suggesting that the normal regulation of GSK-3 is essential for synaptic plasticity [35]. 
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If GSK-3 is altered in AD, then early neuronal dysfunction could be a consequence of this 
disruption of plasticity before tau becomes phosphorylated, aggregated and participates in 
pathological spread.  
 
Given the role of GSK-3 in synaptic plasticity, as well as other functions of neurons such as 
axonal transport [36] then it is not surprising that these functions become perturbed in the 
context of metabolic dysfunction such as insulin resistance, resulting in neuronal dysfunction 
and – for example – cognitive impairment. The finding that a failure of insulin signaling also 
results in AD pathology are in line with the concept that these neuropathological features 
represent a final common pathway of disease with multiple influences including in this 
context insulin signaling but also potentially other processes such as a failure of calcium 
homeostasis  for example [37]. 
 
Insulin signaling as a key regulator of longevity 
This evidence powerfully argues for a role of insulin signaling and its downstream molecules, 
in particular perhaps GSK-3, in AD pathogenesis. It would explain, in part, the 
epidemiological evidence that insulin resistance conditions such as T2DM are risk factors 
for AD. Insulin signaling however is also, remarkably, associated with longevity. In worms, 
flies and mice, perturbations in insulin signaling leading to decreased insulin response also 
lead to a substantially increased lifespan [38-41]. The increase in life span is considerable 
– in some animals a fold change in normal longevity and in mammals up to a 50% increase. 
Both caloric restriction resulting in a decreased responsiveness of the insulin signaling 
pathway and direct knock-out of insulin signaling and associated pathway genes have this 
effect. The effect is so large, and so consistent, that there are reports of people attempting 
to extend their own lives through caloric restriction and many web-sites offer advice on how 
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to do this with various levels of warning about the potential dangers of partial-starvation 
diets. Clearly there is much to recommend avoiding obesity or even the moderate over-
weight state that is becoming the norm in the industrialized nations. Moreover, there is 
consistent evidence from two long primate studies and one long canine study for the benefits 
of caloric restriction on health, although they differ on whether caloric restriction increases 
lifespan in monkeys and dogs as it does in mice [42-45]. However, it remains to be seen, 
and remains highly controversial, as to whether caloric restriction will have effects on 
longevity in man.  
 
Man as an exception to the longevity thesis 
We believe that this argument, which regularly escapes into the non-scientific general 
media, is missing an important observation. Man is not like most other animals. Specifically, 
humans have a notably extended post-fertility lifespan (PFLS). Whilst some life beyond 
fertility is not uniquely human, indeed it is a characteristic shared with many mammalian 
species, as Cohen in his review of the relevant literature points out [46]. Nonetheless, even 
evaluating Cohen’s own review data, it is clear that as a proportion of total life span, humans 
have a remarkable and highly extended PFLS. Women cease to become fecund at a 
maximum age of ~45 years and lifespan in man is recorded to 110 years and above. Also 
from Cohen’s review only one other animal was identified with an extended PFLS similar to 
man – the killer whale, Orcinus Orca, which has a total lifespan of twice the fertility span 
(see reference [46] Table 1). Theories abound regarding why man has such a remarkably 
extended PFLS, the most popular of which is the ‘grandmother hypothesis’ variants of which 
suggest an evolutionary advantage to having members of a close-knit hunter-gatherer unit 
available for child caring and other societal functions [47]. Recently, similar reasoning has 
been extended beyond man to that other mammal with extended PFLS, Orcinus Orca [48-
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50], with a model demonstrating that improved reproductive success in younger individuals 
combined with the usefulness of non-fertile related individuals provides a selection pressure 
that could account for the evolution of menopause and an extended post-fertility life [51].  
 
However, regardless of the evolutionary origins of PFLS, the link between longevity and the 
insulin signaling pathway and between insulin signaling and AD suggests a hypothesis. This 
is that increasing longevity is achieved through increases in PFLS, the molecular 
underpinning of which is a reduced ‘efficiency’ of insulin and IGF signaling (IIS) and as a 
consequence of this reduced IIS, organisms with relatively increased PFLS are at relatively 
increased risk of AD. In such a hypothesis, the ‘efficiency’ of IIS might refer to decreased 
tonic activity or control over the pathway or decreased response, for example, of insulin to 
metabolic stimulus or of cell response to signaling, or some combination thereof. Whatever 
the specific mediators of the general mechanism of ‘efficiency of IIS’, the hypothesis we 
propose here brings some specific predictions. Most obvious, and most testable, is the 
prediction that the molecular and pathological characteristics of AD will be more common in 
animals with a relatively longer PFLS as a proportion of total lifespan. In other words, that 
plaques and tangles and associated molecular events will be correlated not with age per se 
but with longevity. We would predict the features of AD to be associated more with PFLS 
than with lifespan and to be a disease not only of man but of other animals with a long PFLS. 
Specifically, to be a disease in animals such as Orca more than of our closer relatives, such 
as the Chimpanzee.  
 
Do cetaceans, or other diving animals, have dementia? 
We are unaware of any data on AD pathology, let alone cognitive and functional impairment 
in Orca. However, a related cetacean, Stenella coeruleoalba, the striped dolphin, has an 
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average lifespan of ~58 years, and the females drop fecundity at 30 years giving them a 
PFLS of ~ 48 (Prof V Janik, Scottish Oceans Institute, University of St Andrews, personal 
communication), similar to the killer whale. Therefore, we set out to examine this hypothesis 
predicting that an animal with a long PFLS would have evidence of AD pathology hitherto 
not identified in free living, wild animals. To do this, we obtained, 8 brains from stranded 
dolphins from different coastal areas of Spain. RNA extraction from this material allowed the 
identification of the coding region of the APP gene covering the 40-43 amino acid region of 
the A peptide and was shown to be identical across 3 species of dolphins, Tursiops 
truncatus (bottlenose dolphin), Grampus griseus (Risso´s dolphin) and Stenella 
coeruleoalba, and man (Fig. 1A) suggesting that these species of dolphins could generate 
A from the precursor protein. Three specimens belonging to Stenella coeruleoalba species 
were immuno-positive for amyloid plaques and 4 (3 Stenella coeruleoalba and 1 Tursiops 
truncatus) for tau fibrillary tangles. Specifically, 2 types of amyloid deposits were visualised: 
firstly in the parietal cortex as diffuse deposits, and secondly in the cerebellum, the region 
of the brain used for echo-location, where there were structures that resembled more 
compact senile plaques (Fig. 1B). These latter amyloid deposits were up to 50 m in 
diameter and in some areas the plaques were relatively numerous. Neurites surrounding 
these plaques were immunopositive for tau, similar to that seen in cortical amyloid deposits 
in humans. In the frontal cortex, as well as in the parietal cortex, thalamus and cerebellum, 
there was evidence of tau pathology, for example, seen as well-defined neurofibrillary 
threads in the cortex of an adult animal (Fig. 1C). In summary, these studies found evidence 
of both amyloid deposits and tau pathology in stranded dolphins including in the same 
individuals (see for example Figure 1E), making this animal one of very few naturally 
occurring models of an almost uniquely human disease. Clearly it would be of considerable 
interest to know whether the pathology we observe in these animals had effects on cognition 
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and indeed on behaviour and although such studies are unlikely to be achievable in wild 
animals, it may be possible to determine the relationship between AD-like pathology and 
function in captive individuals. We note also with considerable interest that dolphins are also 
prone to T2DM, showing blood based indicators of insulin resistance [52] and possibly being 
a natural model of metabolic syndrome [53]. Whilst this is in line with our hypothesis we 
cannot know if the individuals in this case had such deficits in insulin signaling and response 
in part because the reference values for dolphin are less certain and in part because analysis 
of post-mortem samples for analytes such as glucose and insulin is challenging in man [54, 
55] and, to our knowledge, not informative in cetaceans.  
 
These findings suggest that full AD pathology – as well as T2DM - can occur in free-living, 
wild cetaceans. In addition, recent evidence suggests other changes, perhaps indicative of 
early AD, can be found in other sea mammals. Investigating the stranding and death of sea-
lions suffering from domoic acid toxicosis due to blue-green algae, it has been reported that 
CSF from these animals shows evidence of changes indicative of neurodegeneration [56]. 
Using untargeted mass spectrometry proteomics methods, Neely et al found an excess of 
multiple complement proteins and gelsolin, proteins we and others have reported to be 
associated with AD [57, 58]. Other proteins found in the CSF of these animals include 
Neuronal Cell Adhesion Molecule and Reelin, both proteins previously having been 
implicated in AD pathology [59, 60]. Even more remarkably to our mind is the observation 
of altered Dickkopf 3 protein (DKK3) in sea lion CSF in that study. This is of considerable 
interest as the DKK proteins are the predominant negative regulators of wnt signaling, the 
final effector of which is GSK-3 suggesting a possible link to both insulin signaling and to 
AD pathogenesis. Evidence for a role of DKK in AD abounds. DKK1 is increased by A in 
human brain and in animal models [61], inhibition or silencing DKK1 prevents A induced 
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synaptic loss [62] and we have shown DKK induction by A transmits the toxic signal through 
clusterin to not only neurotoxicity but also tau phosphorylation and cognitive impairment [63]. 
Not surprisingly, given these findings, DKK1 is now of considerable interest as a target for 
therapy [64]. Most of these studies have focused on DKK1 but not excluded the involvement 
of the other, highly similar, DKK proteins; however, in at least one study DKK3 co-localised 
with A pathology in AD brain [65] and was increased in CSF and plasma of people with AD 
[66].  
 
Alzheimer’s disease; just how common is it (in other animals)? 
The finding of both amyloid and tau pathology in dolphins, as we report above, is all the 
more remarkable an observation as AD pathology has only been rarely reported in other 
mammals [67]. In a recent, detailed and comprehensive review of the ageing brain in non-
human animals Youssef et al [67] find evidence of some features of human 
neurodegenerative disease in many animals although note considerable differences from 
human disease and the absence of a natural model linking the twin features of AD (plaques 
and tangles) with each other and neuronal loss and with cognitive impairment. Specifically, 
they note that highly phosphorylated tau but not NFTs are found in sheep, goats, cheetah, 
bison, baboon, and bears. Closer to man, non-human primates, including Chimpanzee, 
Orangutan, Gorilla, Baboon, Rhesus, Cynomolgus and Green monkeys are all found to have 
amyloid plaques but not NFTs (Youssef et al Table 1 [67]) 
 
Just as in many of these animals, previous studies have found evidence in dogs (cross-
breeds and beagles) of amyloid, but not tau pathology [67]. Cohen (Table 1) indicates that 
dogs (beagles) have a PFLS of 23.3, though in reality this is breed specific [68, 69], and 
some families of beagles may be prone to premature senility and develop amyloid deposits 
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but not neuritic plaques [70, 71]. Our hypothesis that PFLS associates with AD pathology 
would predict that breeds with a longer PFLS than Beagle would be likely to have more AD 
pathology including neuritic plaques.  
 
The domestic cat has a longer PFLS than dog, of 38 or more (Gunn-Moore, 2016 personal 
experience), and with reference to T2DM show pathology signs more akin to humans than 
any other non-primate[72]. Moreover, cats develop early amyloid changes but not plaques 
[73, 74] although In unpublished findings noted in Youssef et al [67], Nakayama reports 
neuronal cell loss in the hippocampus of aged cats associated with NFTs composed of highly 
phosphorylated tau. In a recent comprehensive neuropathological study, Chambers et al, 
quite remarkably, found the full extent of AD pathology and proposed the cat as a natural 
model of Alzheimer’s [75].In the context of the cat, many pet animals are neutered, and as 
such their fecundity will have been dramatically reduced, while their PFLS will have been 
markedly increased. Importantly, neutering increases not only longevity in our pets but also 
their risk of obesity, and as indicated above in relation to cats, an increase in T2DM. It is not 
known whether this increase in obesity and T2DM in neutered animals reflects the critical 
change in ‘IIS efficiency’ we postulate to be the molecular mechanism underlying the 
association between PFLS and AD or whether it is central as well as systemic. However, 
our hypothesis would suggest that, to the extent that it does, then evidence of AD pathology 
would be present in aged neutered cats. Just as inter-breed studies in dog might be a means 
to test the hypothesis then studies in neutered cats might be a means to test the underlying 
molecular mechanisms.  
 
 
Conclusions and some suggestions for further study 
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In summary then, the findings we report and review here suggest that, almost uniquely other 
than in man, sea mammals and cats might have AD-like neurodegeneration. This ranges 
from sea lions with domoic acid toxicosis having CSF markers also found in AD, to post-
mortem amyloid and tau pathology in the brains of dolphins. Moreover dolphins are uniquely 
prone to a (pre-) diabetes state and are one of the few animals, alongside other cetaceans 
and man with a naturally long post-fertility lifespan. Cats have both T2DM and recent 
evidence suggests, full AD pathology and also have a moderately long PFLS albeit not as 
long as man and Orca. Is this sharing of AD pathology, diabetes and PFLS important? We 
suggest it is and this then is our hypothesis: that humans, at some point in our evolutionary 
history, acquired an insulin pathway trait characteristic that makes it less responsive to 
external signaling or less effective in transmitting this signal to targets generally or to GSK3 
specifically. This characteristic results in longer life relative to other animals but also the twin 
diseases of T2DM and AD (Figure 2). This hypothesis does not imply that insulin signaling 
effects only longevity, nor that the effects of insulin signaling on metabolism, longevity and 
dementia are necessarily mediated through a single mechanism. Nor even that defects in 
IIS inevitably result in dementia. Clearly there might be independent mechanisms at play 
and indeed for such a critical signaling pathway with pleiotropic actions on fundamental 
processes of physiology it would be surprising if there were not independent influences on 
processes such as metabolism, longevity and dementia. However, here we postulate a 
linked mechanism that led us to hypothesize that animals with unusual longevity would be 
at risk of both insulin resistance and Alzheimer’s disease, a hypothesis that led us to a 
prediction that cetaceans and cats would have AD pathology - a prediction for which we 
have provided some proof. 
 
 15 
This hypothesis has important consequences for our explanatory constructs of human 
evolution and also some testable predictions. First, in evolutionary theory there has been a 
robust debate regarding the PFLS in man with some arguing for the competitive advantages 
offered by the elder in early human societies – the so-called grandmother hypothesis [76]. 
Our proposal suggests that this theory might be arguing after the effect and the evolutionary 
driver may have been at a molecular level and theorists might productively search instead 
for a competitive advantage offered by a relatively less ‘efficient’ or responsive insulin and 
IGF signaling pathway. Secondly, in terms of predictions that follow from our hypothesis, we 
would suggest that AD and T2DM would be relatively less common in non-human mammals 
and moreover pathological features of both diseases would occur most often in those 
animals with a relatively longer PFLS. Some aspects of AD pathology have been reported 
in a wide range of other animals although in almost all cases this is very incomplete making 
our report here of both neuritic plaque and tangle pathology in dolphin all the more 
remarkable. Further studies including large variable biomolecular studies such as those that 
have recently been reported in sea-lion will be of interest in exploring the relationship 
between AD pathology and vulnerability to metabolic dysfunction in sea mammals and cats. 
However, testing the prediction that follows from our hypothesis quantitatively from such 
case reports from wild cetaceans is difficult and we would not advocate the use of captive 
cetaceans as experimental animals. So we propose a specific experiment. Recombinant 
inbred strain mice show both variation in lifespan and lifespan response to caloric restriction 
[77]. Our hypothesis would suggest that these traits would be associated with insulin 
signaling phenotypes and moreover, and more surprisingly, with phenotypes relevant to 
Alzheimer’s disease such as A generation, tau expression and phosphorylation. Finally, a 
word to those individuals practicing caloric restriction to extend lifespan. If we are right, then 
it’s too late; we are already long-lived animals and the price we pay is Alzheimer’s disease.  
 16 
 
Acknowledgements 
Research in the author’s laboratories is supported by the NIHR, MRC, ARUK, Alzheimer’s 
Society, Wellcome Trust and the EU 
 
Competing interests 
The authors declare no competing interests. 
Display items 
Table 1: Lifespan and reproductive span across a range of animals (adapted from 
Cohen [46]) 
Cohen (1994) lists the mean Post Reproductive Life Span (PRLS, equivalent to the Post 
Fertility Lifespan, PFLS, used in the text of this paper and in this table) for a range of animals 
together with their maximum observed lifespan. Here we extract from Cohen, those where 
this data is known and have, where a range is given, have listed the mean value and in 
addition expressed the PFLS as a proportion of lifespan. We add data for man, and assume 
that 110 is a maximum lifespan, although older people have been recorded, and for PFLS 
have assumed a mean age at death of 85 years and a mean age of reproductive cessation 
of 40 years (see http://en.wikipedia.org/wiki/Age_and_female_fertility for discussion of age 
of fertility).  
 
Figure 1: Alzheimer pathology in striped dolphin (Stenella coeruleoalba) brain. (A) 
Aβ42 amino acid alignment between three dolphin species and other mammals. (B) Amyloid 
plaques in cerebellum tissue from a Stenella coeruleoalba specime, AB2 (Araclon Biotech 
antibody, 1:750 specific for human beta-amyloid 40); (C) amyloid plaque in parietal cortex 
from Stenella coeruleoaba AB2 (Araclon Biotech antibody, 1:750 specific for human beta-
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amyloid 40); (D) neurofibrillary tangles in frontal cortex of Stenella coeruleoalba, 5A6 
antibody (Hybridoma Bank, 1:750); (E) neurofibrillary threads and plaques in parietal cortex 
of a single Stenella coeruleaoba specimen, 5A6 antibody (Hybridoma Bank, 1:750) 
 
Figure 2: Insulin signaling protects against Alzheimer’s disease at the cost of 
longevity 
 
We postulate that for a given stimulus the response of the insulin signaling pathway from 
generation of ligand through intracellular signaling to the effector of the pathway in the action 
of GSK3 which is inhibited by insulin signaling, varies giving a relative response that we 
characterize as ‘efficient’ or ‘inefficient’. Species level differences in the efficiency of 
response to stimulus will influence the relative lifespan, risk of type 2 diabetes mellitus 
(T2DM) and risk of Alzheimer’s disease (AD); a highly efficient response resulting in 
relatively shorter lifespan but reduced risk of T2DM and AD whereas a less efficient 
response increases post fertility lifespan (PFLS) and hence longevity but at the expense of 
risk of T2DM and AD. Note that this hypothesis emphasizes that the ‘efficiency’ of the insulin 
response system is as likely to be the actor in the evolutionary pressure resulting in longevity 
in man and Orca as the fact that we are both long lived animals.  
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Table 1: Lifespan and reproductive span across a range of animals (adapted from 
Cohen [46]) 
 
Order Scientific Name Common name 
Maximum 
recorded 
life span 
(years) 
Mean 
PFLS 
(years) 
PFLS as 
a % of 
maximum 
lifespan 
      
Artiodactyla Bos primigenius Cattle 30 5 16.7 
 Cervus elaphus  Red deer  21 3 14.3 
Artiodactyla 
Carnivora 
Ovis canadensis Bighorn sheep  19 2 10.5 
Canis domesticus 
Domestic dog 
(beagle) 15 3.5 23.3 
Felis silvestris catus Domestic cat 21* 8 38 
Carnivora 
Cetacea 
Panthera leo  African Lion 17 1.8 10.6 
Ursus maritimus  Polar bear 30 4 13.3 
Globicephalus 
macrorhyncus 
Short-finned pilot 
whale 63 14 22.2 
Orcinus orcus Killer whale 78 38 48.7 
Primates 
Callithrix jacchus  Common marmoset 10 2 20.0 
Gorilla gorilla Gorilla 30 4.5 15.0 
Primates 
Primates 
Lemur spp.  Lemurs (five spp.) 24 3.5 14.6 
Leontopithecus 
rosalia  Golden lion tamarin 12 4 33.3 
Macaca fuscata Japanese macaque 35 4.5 12.9 
Macaca mulatta Rhesus macaque 35 2.5 7.1 
Macaca nemestrina Pig-tailed macaque 30 4 13.3 
Macaca radiata Bonnet macaque 20 6 30.0 
Macaca sylvanu Barbary macaque 28 5 17.9 
Pan troglodytes 
Common 
chimpanzee 48 9 18.8 
Papio cynocephalus Olive baboon 27 5 18.5 
Primates Papio 
cynocephalus 
/anubis hybrids Baboon 16 3.5 21.9 
Saguinus fuscicollis Saddleback tamarin 12 4 33.3 
Saimiri sciureus Squirrel monkey 19 3.5 18.4 
     
Homo sapiens Man 110 45 40.9 
      
      
 
PFLS – post-fertility lifespan. 
*But very occasional much older cats have been found – e.g. 32 years of age (seen by author 
DGM). Importantly, long-lives cats are typically neutered. 
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